Oral FT-4202 Safe, Found to Improve Red Blood Cell Function in SCD

Oral FT-4202 Safe, Found to Improve Red Blood Cell Function in SCD

282165

Oral FT-4202 Safe, Found to Improve Red Blood Cell Function in SCD

FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), is well-tolerated in people with SCD and induces improvements in several red blood cell parameters, early clinical trial data indicate. The results observed in this initial group of patients support the efficacy of Forma Therapeutics‘ investigational medication, as well as the dosing of a second group with a higher daily dose. The findings were revealed in “FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of…

You must be logged in to read/download the full post.